In the offering, the Boca Raton, Fla.-based floated 2.2 million shares at $6.80 apiece, for gross proceeds just shy of $15.0 million. The offering also includes a 30-day underwriter’s option to purchase an additional 330,882 shares for the same price, which would pull in another $2.3 million if exercised in full.
Sensus said it plans to use net proceeds for general corporate purposes, including R&D, expansion of product lines and roll-out of new products.
B. Riley FBR was lead underwriter and sole book-runner for the offering, with Craig-Hallum Capital Group and Roth Capital Partners as co-managers for the offering and Maxim Group as financial advisor.
Last month, Sensus Healthcare said that it won FDA 510(k) clearance for its SRT-100+ next-gen superficial radiation therapy system.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.